Fig. 6
Diagram with proposed stratification of patients into targeted therapeutic regimens according to somatic and germline mCLM profiles. Numbers represent IDs of individual patients: TMB-H patients in light red, patients with MMR-D status in dark red, HRR in blue, KRAS wild type in green, KRAS mutated in orange (*KRASG12C), and TP53 mutated in violet. KRAS wild type patients eligible for the anti-EGFR therapy in the left column and the rest of patients with targetable mutations in the right column. Some patients belong to more groups based on their mutational profiles. Footnotes: *Patients with somatic KRASG12C variant (n = 2). †Patients with somatic variants in PIK3CA (n = 6; three p.E545K, one p.R93W, p.N345K, and p.Q546K) pathogenic or likely pathogenic by ClinVar